Ocugen Inc. says it is ready to take its combination product OCU310 into Phase III after unveiling top-line Phase II data demonstrating tolerability of the two-drug combo. Promising trends for signs and symptoms of the disease could wind up as advantages on the market, should they hold up in Phase III.
The Malvern, Pa.-based firm revealed March 20 that OCU310, a twice-daily eye drop composed of the alpha 2 adrenergic receptor...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)